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Three types of human interferon (Hu IFN) have to date been characterized in terms of physicochemical properties and serology (1) . Hu IFN-a and -fl are mainly produced by leukocytes and fibroblasts, respectively, and are pH 2 stable but antigenically distinct (2, 3). Hu IFN-T, produced by lymphocytes (4, 5) and T cell clones (6, 7) during mitogenic or specific antigenic stimulation, is pH 2 labile and shows no antigenic cross-reactivity with a or fl (5) . There are also differences in cross species reactivity between the IFN types: a-IFN is active not only in homologous cells but in other mammalian species, whereas 7-IFN is more strictly species specific (8, 9) . However, we have found that when lymphocytes from individuals who have recently received influenza vaccine are stimulated in vitro with this virus, a novel IFN is produced that is pH 2 labile, but is neutralized by an antiserum to a-IFN and has activity on heterologous cells. This pH 2-labile a-IFN resembles an IFN that has been found in the serum of patients with systemic lupus erythematosus (SLE) (10). Cell Separation and Culture. Peripheral blood mononuclear cells (PBM) were separated from heparinized venous blood samples by centrifugation over Ficoll-Hypaque. 10 PBM were cultured at 10e/ml in upright plastic flasks (3013; Falcon Labware, Oxnard, CA) in bicarbonatebuffered RPM1 1640 medium with added 10 mM Hepes buffer and 10% AB human serum. To obtain optimal stimulation of vaccinated volunteers, PBM were stimulated with a mixture of equal proportions of sucrose density gradient-purified influenza viruses A/JAP(H2Nz), A/ X31(H3N2), and A/BRAZIL (H1Na) at a final concentration for the mixture of 1.2 pg/ml. After 4 and 6 d in vitro stimulation, supernatants were sampled and aliquots were stored at -70°C until assayed. After sampling the volume of the cultures was made up by addition of fresh medium sampling.
Materials and Methods

Vaccination of
Interferon Assays. aliquot of supernatant were determined; for neutralization studies the antiserum was added in the appropriate quantity to neutralize this IFN and incubated for 4 h at room temperature before assaying. Supernatants were left at pH 7 or acidified to pH 2 for 20 h at 4°C. c~-IFN Controls. Purified Hu IFN-a derived from Namalwa cells induced by Sendai virus was used as a control. This IFN is known to contain at least eight subtypes of cMFN (12) and had a specific activity of 2.8 X l0 s U/mg protein.
Results
PBM were separated from peripheral blood samples taken at intervals after vaccination from a normal volunteer and were cultured in vitro with or without influenza virus. In all cultures with the virus, blastogenic transformation and proliferation of lymphocytes occurred. Typically, the 125Iododeoxyuridine incorporation in unstimulated cultures after 6 d in vitro was <100 cpm and in influenza-stimulated cultures was >3,000 cpm/105 cells. Table I shows the characterization of the IFN present in samples taken at the 4th or 6th d of in vitro culture of PBM with influenza virus. The PBM cultures from four volunteers were set up 7 d after vaccination. No IFN was produced in unstimulated cultures.
As shown in Table I , the IFN produced in the influenza-stimulated cultures was in all cases strongly inactivated by pH 2 treatment for 20 h but was also neutralized by an antiserum to Hu IFN-c~. However, PBM cultures set up at the same time and stimulated with the mitogen concanavalin A (Con A), an inducer of y-IFN, produced a pH 2-labile IFN that was not significantly neutralized by the a-IFN antibody. Throughout this series of experiments, PBM from donor GH failed to produce high levels of IFN when stimulated with Con A. Controls of e~-IFN, induced by Sendai virus in Namalwa cells, Hu IFN-~N, and known to contain at least eight subtypes of c~-IFN (12), were set up with each experiment and showed no inactivation with the pH 2 treatment, but total neutralization with the c~ antiserum (Table I) .
Further experiments showed us that this acid-labile a-IFN was the predominant IFN produced in influenza-stimulated cultures from the four vaccinated individuals set up at various times after vaccination. So far we have examined cultures up to 49 The IFN activity in the supernatants was assayed on WISH ceils as described in Materials and Methods. Supernatants from cultures of PBM from PB were harvested after 4 d of in vitro culture, and from BA, MY, and GH after 6 d. a-IFN controls consisted of highly purified Hu IFN-a as described in Materials and Methods. (Table  III) . This IFN had greater activity on monkey and bovine cells than the IFN from Con A-induced supernatants, although it did not show the same cross-reactivity as * The difference between these two groups was found to be highly significant by the Wilcoxon two-sample rank sum test (P < 0.0001). MDBK cells in simultaneous BRIEF DEFINITIVE REPORT conventional c~-IFN. Hu IFNa-N had equal activity on human and monkey cells and three-to fourfold more activity on bovine cells, as shown in Table III . We also investigated the heat lability of the different IFN activities. Con A-and influenzastimulated PBM supernatants were almost completely inactivated by a 15-rain incubation at 56°C (mean inactivation 87 and 90%, respectively) whereas Hu IFNc~N was not significantly inactivated (mean inactivation, 17%).
Discussion
The unusual IFN activity described in this paper probably represents an as yet uncharacterized subtype of ~-IFN. There are 10 or more genes coding for different a-IFN (13), the products of which are not all clearly defined in terms of physicochemical properties. Acid-stable c~-IFN is produced by leukocytes challenged with a variety of viral and nonviral stimuli (1, 8, 14, 15) and in vitro production of acid-labile IFN has been briefly mentioned in two previous studies (9, 16) , but no detailed characterization has been done. In vivo acid-labile ~-IFN has been described in the sera of mice infected with murine cytomegalovirus (17, and Dr. Jane Allen, personal communication) and in patients with SLE (10).
We do not know what subtype of blood mononuclear cell produces this acid-labile ~-IFN. Ennis and Meager (18) have reported the production of Hu IFN-y in an in vitro immune response to influenza virus in vaccinated individuals, but there are significant differences between their system and ours. In their experiments lymphocytes were stimulated with influenza virus in such a way as to generate cytotoxic T cells (19) , whereas our cultures are known to produce helper T cells (20, 21) . It will be of interest to see whether the production of different IFN types is related to different effector T cell subtypes; such experiments are currently underway.
Summary
We have described in this paper a novel human interferon (IFN) with antigenic and cross-species reactivity of a-IFN and physicochemical properties of y-IFN. This IFN is produced by normal peripheral blood mononuclear cells during an immune response but has also been associated with autoimmune disease (10). The system described here will be useful in elucidating the biological significance and cell of origin of this IFN.
